Improved risk assessment through incorporation of a prognostic 31-gene expression profile test for AJCC stage IB-IIA cutaneous melanoma

Introduction: Risk assessment is critical for guiding patient care decisions and treatment of cutaneous melanoma (CM), especially as options in the adjuvant setting expand. Additional prognostic tools are needed because many patients who die from melanoma are initially diagnosed with stage I-II disease. A 31-gene expression profile (31-GEP) test has been shown to have prognostic accuracy and inform follow-up intensity, sentinel lymph node biopsy (SLNB) guidance, surveillance, and possibly adjuvant therapy in stage I-III CM.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research